Eli Lilly and Company (NYSE:LLY) Stock Holdings Lowered by Woodline Partners LP

Woodline Partners LP decreased its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 11.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 101,809 shares of the company's stock after selling 12,618 shares during the period. Woodline Partners LP's holdings in Eli Lilly and Company were worth $78,597,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Victrix Investment Advisors purchased a new stake in shares of Eli Lilly and Company during the fourth quarter worth about $936,000. Vident Advisory LLC increased its stake in shares of Eli Lilly and Company by 16.0% during the fourth quarter. Vident Advisory LLC now owns 32,617 shares of the company's stock worth $25,182,000 after purchasing an additional 4,500 shares in the last quarter. Vienna Asset Management LLC purchased a new stake in shares of Eli Lilly and Company during the fourth quarter worth about $1,254,000. Virtus Investment Advisers Inc. purchased a new stake in shares of Eli Lilly and Company during the fourth quarter worth about $154,000. Finally, Visionary Wealth Advisors increased its stake in shares of Eli Lilly and Company by 28.0% during the fourth quarter. Visionary Wealth Advisors now owns 2,153 shares of the company's stock worth $1,662,000 after purchasing an additional 471 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Down 3.0%

LLY traded down $22.73 during trading on Wednesday, hitting $724.28. The company had a trading volume of 4,054,290 shares, compared to its average volume of 3,606,606. The company has a market cap of $686.43 billion, a PE ratio of 61.85, a P/E/G ratio of 1.40 and a beta of 0.48. The business has a 50-day moving average of $793.65 and a 200-day moving average of $804.27. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). The company had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The company's revenue was up 45.2% on a year-over-year basis. During the same period in the prior year, the company earned $2.58 earnings per share. As a group, analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be paid a dividend of $1.50 per share. The ex-dividend date is Friday, May 16th. This represents a $6.00 annualized dividend and a yield of 0.83%. Eli Lilly and Company's payout ratio is 48.82%.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. The trade was a 14.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.13% of the stock is owned by insiders.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Wells Fargo & Company reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Truist Financial boosted their target price on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a report on Monday, February 3rd. Guggenheim restated a "buy" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Hsbc Global Res downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. Finally, HSBC downgraded shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and dropped their target price for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. One analyst has rated the stock with a sell rating, two have given a hold rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $1,011.37.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.